• Skip to main content
  • Skip to secondary menu
  • Skip to primary sidebar
  • Skip to secondary sidebar
  • Skip to footer

  • Opinion
  • Health IT
    • Behavioral Health
    • Care Coordination
    • EMR/EHR
    • Interoperability
    • Patient Engagement
    • Population Health Management
    • Revenue Cycle Management
    • Social Determinants of Health
  • Digital Health
    • AI
    • Blockchain
    • Precision Medicine
    • Telehealth
    • Wearables
  • Startups
  • M&A
  • Value-based Care
    • Accountable Care (ACOs)
    • Medicare Advantage
  • Life Sciences
  • Research

Subsense Emerges from Stealth with $17M to Develop Non-Surgical Brain-Computer Interface

by Fred Pennic 02/18/2025 Leave a Comment

  • LinkedIn
  • Twitter
  • Facebook
  • Email
  • Print

What You Should Know: 

– Subsense, Inc., a pioneering neurotechnology company announced its official launch and the closing of a $17 million seed funding round led by Golden Falcon Capital. 

– The company is developing a groundbreaking non-surgical, nanoparticle-based Brain-Computer Interface (BCI) with the potential to transform the treatment of neurological conditions.

Nanoparticle-Based Technology Aims to Enhance Treatment of Neurological Conditions

Subsense is co-founded by Tetiana Aleksandrova, a neurotechnology entrepreneur with a passion for developing innovative solutions for brain health and Artem Sokolov, a serial entrepreneur and early investor in successful companies like Asana, SoFi, and Coursera.Subsense’s innovative technology utilizes nanoparticles to establish a bidirectional connection between the brain and external devices. This approach allows for targeted neural stimulation and precise monitoring, opening up new possibilities for treating a wide range of neurological disorders.

“Brain-computer interfacing promises to unlock limitless human potential, but innovation has been held back by a lack of effective non-surgical approaches,” said Tetiana Aleksandrova, Subsense’s Chief Executive Officer. “By delivering nanoparticles that bind with receptors in the brain, Subsense can achieve more extensive connectivity with a far gentler approach.”

Collaborating with Leading Research Institutions

Subsense is collaborating with a consortium of leading neurological research institutions, including UC Santa Cruz and ETH Zurich, to accelerate the development and validation of its technology.

Targeting Neurological Conditions

Subsense’s initial focus is on developing therapies for neurological conditions such as:

  • Parkinson’s disease
  • Alzheimer’s disease
  • Epilepsy
  • Depression
  • Stroke
  • Chronic pain

Expanding the Possibilities of Brain-Computer Interfaces

Beyond therapeutic applications, Subsense is also exploring more expansive possibilities for its technology, including:

  • Sensorimotor recovery: Restoring vision, hearing, and movement.
  • Inner speech decoding: Translating thoughts into words.
  • AI integration: Merging the human brain with artificial neural networks.
  • External memory: Creating a backup and extension of human memory.
  • Mental health regulation: Monitoring and controlling emotions and mood.
  • Appetite control: Managing hunger and satiety signals.
  • LinkedIn
  • Twitter
  • Facebook
  • Email
  • Print

Tap Native

Get in-depth healthcare technology analysis and commentary delivered straight to your email weekly

Reader Interactions

Primary Sidebar

Subscribe to HIT Consultant

Latest insightful articles delivered straight to your inbox weekly.

Submit a Tip or Pitch

Featured Insights

 Selecting the Right EMR: A Practical Guide to Streamlining Your Practice and Enhancing Patient Care

Selecting the Right EMR: A Practical Guide to Streamlining Your Practice and Enhancing Patient Care

Featured Interview

Virta Health CEO: GLP-1s Didn’t Kill Weight Watchers, Its Broken Model Did

Most-Read

Health IT Sector Navigates Policy Turbulence with Resilient M&A

Health IT’s New Chapter: IPOs Return, Resilient M&A, Valuations Rise in 1H 2025

PwC Report: US Medical Cost Trend to Remain Elevated at 8.5% in 2026

PwC Report: US Medical Cost Trend to Remain Elevated at 8.5% in 2026

Philips Launches ECG AI Marketplace, Partnering with Anumana to Enhance Cardiac Care with AI-Powered Diagnostics

Philips Launches ECG AI Marketplace, Partnering with Anumana to Enhance Cardiac Care with AI-Powered Diagnostics

WeightWatchers Emerges from Bankruptcy, Launches New Menopause Program

WeightWatchers Emerges from Bankruptcy, Launches New Menopause Program

CMS Finalizes New Interoperability and Prior Authorization Rule

CMS Proposes 2026 Physician Fee Schedule Rule: Boosting Primary Care, Cutting Waste, and Modernizing Payments

Beyond SaaS: How Agent as a Service is Transforming Healthcare Automation

Beyond SaaS: How Agent as a Service is Transforming Healthcare Automation

New Strategies Needed: No Surprises Act and the Challenges for Payors with Provider Data Inaccuracies

Samsung Acquires Xealth to Accelerate Connected Care Vision

Samsung Acquires Xealth to Accelerate Connected Care Vision

AI Dominates Digital Health Investment in First Half of 2025

Rock Health Report: AI Dominates Digital Health Investment in First Half of 2025

Moving Beyond EHRs: What Lies Ahead for Healthcare Digitization?

AI Agents vs. Chatbots: Understanding Agentic AI’s Role in Healthcare

Secondary Sidebar

Footer

Company

  • About Us
  • Advertise with Us
  • Reprints and Permissions
  • Submit An Op-Ed
  • Contact
  • Subscribe

Editorial Coverage

  • Opinion
  • Health IT
    • Care Coordination
    • EMR/EHR
    • Interoperability
    • Population Health Management
    • Revenue Cycle Management
  • Digital Health
    • Artificial Intelligence
    • Blockchain Tech
    • Precision Medicine
    • Telehealth
    • Wearables
  • Startups
  • Value-Based Care
    • Accountable Care
    • Medicare Advantage

Connect

Subscribe to HIT Consultant Media

Latest insightful articles delivered straight to your inbox weekly

Copyright © 2025. HIT Consultant Media. All Rights Reserved. Privacy Policy |